HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMS-986141

Also Known As:

4-(4-(((6-Methoxy-2-(2-methoxyimidazo(2,1-b)(1,3,4)thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N,N-dimethylbenzamide

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kong, Yi: 1 article (12/2021)
2.	Li, Shanshan: 1 article (12/2021)
3.	Liu, Shangde: 1 article (12/2021)
4.	Xie, Roujie: 1 article (12/2021)
5.	Yuan, Duo: 1 article (12/2021)
6.	Zhu, Xiong: 1 article (12/2021)
7.	Aronson, Ronald: 1 article (11/2020)
8.	Everlof, J Gerry: 1 article (11/2020)
9.	Garonzik, Samira M: 1 article (11/2020)
10.	Luettgen, Joseph: 1 article (11/2020)

Related Diseases

1.	Thrombosis (Thrombus) 12/01/2023 - "BMS-986141 has the potential to improve the benefit–risk of antiplatelet therapy in patients with atherothrombosis." 12/05/2021 - "To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. " 11/01/2020 - "In the presence of factor Xa inhibition, PAR4 antagonism with BMS-986141 further reduces thrombus formation, especially under conditions of high shear stress. " 11/01/2020 - "Combination of BMS-986141 with apixaban caused a further modest reduction in total thrombus area (9.6%-12.4%), especially under conditions of high shear stress (P≤0.027). "
2.	Hemorrhage 12/01/2023 - "BMS-986141 is safe and well tolerated, with dose-proportional pharmacokinetics and concentration-dependent pharmacodynamics in healthy participants over a wide dose range.BMS-986141 has robust antithrombotic activity and low bleeding risk.What" 12/01/2023 - "BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist that exhibited robust antithrombotic activity and low bleeding risk in preclinical studies. "

Related Drugs and Biologics

1.	protease-activated receptor 4
2.	BMS-986120
3.	Factor Xa (Coagulation Factor Xa)
4.	apixaban

Related Therapies and Procedures

1.	Therapeutics